Literature DB >> 15354267

Platelet coagulation-protein interactions.

Peter N Walsh1.   

Abstract

The biochemical mechanisms by which activated platelets participate in exposing receptors for the assembly of enzyme-cofactor-substrate complexes at all stages of the blood coagulation cascade are reviewed. Information derived from studies conducted during the last 30 years supports the concept that the initiation of blood coagulation is triggered by exposure of tissue factor at injury sites, leading to the generation of minute quantities of thrombin (limited by tissue factor pathway inhibitor), sufficient to activate platelets, factors XI, VIII, and V, and trigger the consolidation pathway (i.e., the sequential activation of factors XI, IX, X, and prothrombin on the activated platelet surface), leading to the generation of sufficient thrombin to convert fibrinogen to fibrin and effect hemostasis. Platelets localize coagulation to the hemostatic thrombus and protect coagulation enzymes from inhibition by both plasma and platelet inhibitors (e.g., protease nexin 2), thus preventing disseminated intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354267     DOI: 10.1055/s-2004-833481

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  19 in total

1.  PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium.

Authors:  Fredda S London; Mariola Marcinkiewicz; Peter N Walsh
Journal:  Biochemistry       Date:  2006-06-13       Impact factor: 3.162

Review 2.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

3.  Extensive deendothelialization and thrombogenicity in routinely prepared vein grafts for coronary bypass operations: facts and remedy.

Authors:  Dominik R Weiss; Gerd Juchem; Bernhard M Kemkes; Brigitte Gansera; Stephan Nees
Journal:  Int J Clin Exp Med       Date:  2009-05-28

4.  NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry.

Authors:  Heng-Lan Kuo; Jin-Cherng Lien; Chien-Hsin Chang; Ching-Hu Chung; Sheng-Chu Kuo; Chun-Chieh Hsu; Hui-Chin Peng; Tur-Fu Huang
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

5.  Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.

Authors:  Christoph B Olivier; Patrick Weik; Melanie Meyer; Susanne Weber; Philipp Diehl; Christoph Bode; Martin Moser; Qian Zhou
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 6.  Historical perspective and future directions in platelet research.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

7.  D-Dimer and Fibrin Degradation Products Impair Platelet Signaling: Plasma D-Dimer Is a Predictor and Mediator of Platelet Dysfunction During Trauma.

Authors:  Christopher C Verni; Antonio Davila; Carrie A Sims; Scott L Diamond
Journal:  J Appl Lab Med       Date:  2020-11-01

Review 8.  Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.

Authors:  Ulla Hedner; Nikolai C Brun
Journal:  Neuroradiology       Date:  2007-07-26       Impact factor: 2.804

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.

Authors:  Huili Wang; Maria Morales-Levy; Jason Rose; Lantz C Mackey; Peter Bodary; Daniel Eitzman; Jonathon W Homeister
Journal:  Am J Pathol       Date:  2013-04-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.